Manufacturers report positive results for deucravacitinib in phase III eczema trial
In the POETYK PSO-1 study, this tyrosine kinase 2 inhibitor was superior to placebo in achieving PASI 75 and Physician’s Global Assessment (sPGA) score of clear or almost clear after 16 weeks. Manufacturers also state superiority to the apremilast active comparator arm.
Source:
Biospace Inc.